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Abstract: Activated protein C (APC) is a major control system of blood coagulation. APC prevents coagulation pathway 
by degrading Va and VIIIa plasma’s coagulation factors. Protein C activation requires its binding to specific endothelial 
cell receptor (EPCR). APC binding to EPCR also activates a wide range of defense mechanisms (anti-inﬂammatory, anti-
apoptosis…). EPCR expression by cells can be detected by various methods, including immunoanalysis and molecular bi-
ology. However, no assays evaluate its functionality. A method, inspired of a standard fibrinoformation time assay, was 
developed to estimate EPCR ability to bind APC on living cell surface in vitro. Endothelial cells were incubated with 
APC and fibrinoformation on cells was followed by spectrophotometry (plasma absorbance increases with fibrin polym-
erization). Membrane-bound EPCR retain APC, thus prolonging fibrinoformation time in a dose-dependent manner. Con-
trol was realized with EPCR-negative cells. This new method can be used on any cell type to study the expression of other 
coagulation receptors. 
Keywords: Thrombosis, activated partial thromboplastin time, endothelial protein C receptor, activated protein C, Endothelial 
protein C receptor functionality analysis. 
INTRODUCTION 
  Bleeding time is widely used as a screening test for pri-
mary hemostasis or platelet-vessel interaction and, as such, is 
a measurement of intrinsic function. Hemophilia diagnosis 
was originally based on the presence of a prolonged whole 
blood clotting time.  
  The transformation of soluble fibrinogen into insoluble 
fibrin is a crucial step of thrombus generation and requires 
the presence of phospholipids (as a component of platelet) 
and calcium. The partial thromboplastin time (PTT) is the 
fibrinoformation time of plasma mixed with exogenous 
phospholipids (cephalin) and calcium chloride [1]. The test 
is termed "partial" due to the absence in the reaction mixture 
of tissue factor, the major cellular initiator of blood coagula-
tion. The addition of kaolin, a non-specific surface activator, 
shortens the coagulation time and makes it much more re-
producible [2]. Compared to PTT, this method is named ac-
tivated PTT (aPTT). Since its introduction, aPTT spread rap-
idly throughout the clotting community. PTT/aPTT are 
nowadays standard screening tests employed in clinical labo-
ratories for the diagnosis of coagulation deficiencies.  
  This test actually remarkably optimizes research on the 
anticoagulant pathway and elucidation of thrombophilia 
pathogenic mechanisms [3]. Increasing numbers of aPTT test 
systems are nowadays commercially available and they dif-
fer in chemical composition of the reagent, activator and the 
method of endpoint detection [4,5]. In these systemes, the 
coagulation process is mainly followed by spectrophotome-
try since plasma absorbance increases with fibrinoformation. 
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  Besides aPTT important conceptual role in our under-
standing of hemostasis in vitro, this method had major im-
pact on elucidation of activated protein C (APC) resistance 
underlying molecular mechanisms [6-8]. APC acts as a ma-
jor control system for thrombosis through negative feedback 
of fibrin generation. Synthesized by the liver as a zymogen, 
protein C (PC) binds its receptor on endothelial cell surface 
(endothelial protein C receptor or EPCR) in order to be acti-
vated. Activated protein C together with its cofactor prevents 
coagulation pathway by degrading two factors essential for 
clotting to occur (FVIIIa and FVa) [9-13]. Moreover, the 
binding of APC to its receptor EPCR activates a wide range 
of defense mechanisms in the host such coagulopathic and 
anti-inﬂammatory reactions [14], calcium flux [15], metallo-
proteinase production [16], and anti-apoptosis [17,18] to 
name just a few.  
  EPCR expression by cells can be detected by various 
assays, including immunocytochemistry, molecular biology 
or soluble EPCR quantitative immunodetection. However, to 
our knowledge, no assays evaluate EPCR functionality in 
situ. A method, inspired of aPTT, was developed to estimate 
EPCR ability to bind APC on cell surface [19]. Cells were 
incubated with APC and fibrinoformation of a plasma added 
onto cells was evaluated by spectrophometry analysis. APC 
trapped on endothelial membrane, correlated to the amount 
of EPCR expressed by those cells, would increase plasma-
clotting time.  
MATERIALS AND METHODS 
Reagents 
Plasma  
  Blood samples were provided from the haematology de-
partment, at the Hotel Dieu hospital (Paris, France). Blood 
was anticoagulated in buffered sodium–citrate and plasma 50    The Open Biochemistry Journal, 2009, Volume 3  Ducros et al. 
were obtained after 30min centrifugation (2000g). All sam-
ples were frozen at -80
oC until they were analysed. To avoid 
any bias due to haemostasis factors abnormalities, a mini-
mum of 5 different plasmas were pooled and homogenised 
for each experiment.  
Cells 
  Human endothelial bone marrow (HBMEC) cell line, 
provided from Dr Pienta, [20] was cultured in 75-cm culture 
dishes containing Endothelial Basal Medium (EBM) sup-
plemented with 10% fetal bovine serum (FBS), 5 mM L-
glutamine, 200 IU/ml penicillin and 10 g/ml streptomycin 
(PAA Laboratories Inc, Etobicoke, ON, USA) according to 
the recommendations of the supplier. The human breast ade-
nocarcinoma cell line MCF7 was grown in RPMI 1640, as 
described above.  
  Various reagents were obtained from different sources as 
follows: human recombinant APC (Lilly, Suresnes, France), 
PTT-LA reagent which contains a phospholipid (cephalin) 
and a particulate activator (micronized silica) in a buffered 
medium, and CaCl2 (generously provided by Diagnostica 
Stago).  
RT-PCR Analysis 
  Human endothelial cells RNA extracts were prepared 
using the Nucleospin RNA-II kit (Macherey-Nagel EURL, 
Hoerdt, France). Briefly, five million bone marrow endothe-
lial cells were washed with ice-cold PBS and lysed with a 
specific buffer that prevents RNA degradation and enhances 
RNA adsorption to the silica membrane of the filtration col-
umn. DNAse I was then directly applied to the membrane to 
digest contaminating DNA. After several washes, pure total 
RNA was finally eluted with RNase-free water.  
  One microgram of total RNA was used for reverse tran-
scription into the complementary DNA (cDNA). RNA was 
denatured for 5 min at 65°C and incubated 30 min at 42°C in 
a final volume of 20 L in an appropriate buffer (Tris HCl 
pH 8.8 5 M, (NH4)2SO4 2 M, MgCl2 1 M) with 1.25 mM 
dNTP (Sigma), 10 pmol oligo(dT) (Promega) and 200 units 
of M-MLV reverse transcriptase (Gibco, Paisley, UK). A 
control was performed without reverse transcriptase. The 
mixture was heated to 72°C for 3 min at the end of the reac-
tion. 
  The polymerase chain reaction (PCR) was performed on 
transcribed cDNA, using specific primers of EPCR genes 
(sense: 5'-CAACTTCAGGATGTTGACAA-3'; antisense: 5'- 
CTACAGCCACACCAGCAAT-3'). These synthetic primers 
were designed with Primer3 program, BLAST verified and 
synthesized by Eurobio (Les Ulis, France). The reaction mix-
ture consisted of 15 ng cDNA, 2.5 units Taq DNA polym-
erase (Gibco), 200 mM dNTP, 0.2 mM of the respective oli-
gonucleotide primers, 10 mM Tris-HCl, pH 8.3, 50 mM KCl 
and 1.5 mM MgCl2 in a final volume of 50 l. The mixture 
was amplified in a thermal cycler (GeneAmp 9600, Perkin 
Elmer, Wellesley, USA). Denaturation was carried out at 
94°C for 1 min, followed by annealing step at 55°C for 1 
min and an extension step at 72°C for 1 min to a total of 35 
cycles. Controls without reverse transcriptase or cDNA or 
using beta2-microglobulin primers were similarly amplified 
in parallel. The PCR products (15 L) were electrophoresed 
on 1.2% agarose gels (Gibco) in 0.45 mM Tris-borate con-
taining 0.2% ethidium bromide and 1 mM EDTA. The gels 
were photographed along with a 100 bp DNA ladder, which 
had been run concurrently as a size marker.  
Immunocytochemistry 
  Five thousand HBMEC were grown in glass bottom 
chamber slides (Lab Tek, Nunc, Naperville, IL, USA) and 
rapidly fixed and permeabilized with ice-cold methanol. Af-
ter three washes with PBS, the non-specific binding was 
saturated by exposure to 10% bovine serum albumin (BSA) 
in PBS for 15 min. The cells were thereafter incubated for 1 
h at room temperature with 20 g/ml of EPCR specific anti-
bodies (AF2245, R&D Systems, Minneapolis, MN, USA), 
and then washed with PBS. The slides were then incubated 
successively with appropriate biotinylated secondary anti-
bodies and streptavidin fluorescein (Amersham, Bucking-
hamshire, UK). Isotypic control was performed and cells 
nuclei were DAPI-labelled. Bound fluorescein was directly 
observed on a Nikon fluorescence microscope. For FACS 
analysis, endothelial cells were detached using accutase 
(PAA) and immunolabelled, without preliminary fixation, as 
previously described. A negative control was performed us-
ing goat IgG1 isotype control (Southern Biotech, Birming-
ham, AL, USA). EPCR expression was analysed with FACS 
Calibur.  
Functionality Assay 
  Activated partial thromboplastin time (aPTT) is a test 
measuring clotting time in plasma, leading to evaluate intrin-
sic clotting pathway efficiency. In order to activate this path-
way, phospholipid and a particulate activator (PTT-LA) and 
calcium are mixed with a plasma sample. The time is 
measured until thrombus formation. To confirm APC effi-
ciency to increase aPTT of normal plasma, 20 L APC at 
different concentrations (dilution in serum-free medium) 
were added to mixed plasma and PTT-LA. Clot formation 
kinetics was then compared between plasma samples with 
and without APC.  
  A method, inspired of the aPTT, has been developed to 
estimate the expression by any type of cells of EPCR, the 
receptor of the anti-thrombotic molecule activated protein C. 
Cells were incubated with APC and clotting time of plasma 
added onto cells was measured. Membrane-bound EPCR 
would retain APC which degrade coagulation factors Va and 
VIIIa, thus increasing plasma clotting time.  
  Thirty thousand HBMEC were seeded on a 96-well plate 
(tissue-culture test plate, TPP, Trasadingen, Switzerland) and 
incubated overnight with appropriate culture medium. The 
day after, cells were washed and incubated with APC (1 to 
50  g/mL, 15min at 4°C). Controls were performed with 
serum-free medium. Cells were then washed repeatedly with 
the culture medium devoid of serum, and further incubated 
with normal plasma and PTT-LA (100 L each, 3 min at 
37°C). PTT-LA reagent contains a phospholipid (cephalin) 
and a particulate activator (micronized silica) in a buffered 
medium. CaCl2 (25 mM) was finally added to the mix to 
trigger coagulation. The optical density (OD) of each well 
was determined by a spectrophotometer at 37°C (Wallac 
Multilabel Counter 1420, PerkinElmer, Waltham, MS, 
USA). APC incubations were realized at 4°C to avoid any 
putative receptor internalization whereas clotting assays Endothelial Protein C Receptor Functionality Analysis  The Open Biochemistry Journal, 2009, Volume 3    51 
were performed at 37°C, temperature suitable for haemosta-
sis enzymes activity. Several wavelengths were tested (from 
355 to 595nm). A measure was achieved every minute and 
plasma aPTT in presence of cells incubated with APC was 
compared to aPTT realised with untreated cells. Results are 
expressed as clots formation kinetics. 
RESULTS AND DISCUSSION 
  To certify the endothelial phenotype of the HBMEC cell 
lines used as a model, expression of some typical markers 
(vWF, E selectin, VEGF R-2 and EPCR) were assessed by 
gene array, PCR and immunocytochemistry (results not 
shown). To ensure the synthesis of endothelial protein C 
receptor (EPCR) mRNA by the endothelial cell lines, a RT-
PCR using specific primers of EPCR was performed on 
HBMEC. The corresponding electrophoresis gel presented 
an amplification band at 692 bp, consistent with the size pre-
dicted, whereas water control was negative (Fig. 1, panel A). 
Expression of EPCR was confirmed by immunocytochemis-
try, using specific antibodies (Fig. 1, panel B).  
  Increasing number of automated coagulation analysers, 
using turbidimetric and absorbance technologies, are com-
mercially available. However standard 405 nm light filter 
permits various coagulation and fibrinolysis tests, various 
wavelengths have already been tested to assess clot forma-
tion (350nm [21]; 570nm [22]).  
  Optimal wavelength to study fibrinoformation was thus 
determined as follow. Plasma, PTT-LA and calcium were 
mixed in a 96-well plate and clot formation kinetics were 
analysed at different wavelengths (Table 1). Optical densities 
vary a lot from plasma to another, it seemed thus important 
to select a wavelength that confers to plasma a lowest absor-
bance to reduce these discrepancies. The choice of 595 nm 
was finally made even though an upper absorbance range 
could have discriminated more efficiently unclotted and clot-
ted state.  
  APC efficiency to increase aPTT of normal plasma was 
then confirmed. APC induces a dose-dependent aPTT pro-
longation, as shown on Fig. (2). Kinetic obtained with 
0.1g/mL APC was similar to the control (results not 
shown), which ensures the reproducibility of the method. 
Literature recommends an APC concentration range of 1-100 
g/mL to detect its anticoagulant effects or intracellular 
properties [23,24]. Our findings are in agreement with these 
previous works.  
  Endothelial cells were then seeded on a culture plate and 
exposed to APC for 15 min. The incubation was performed 
 
 
 
 
 
 
 
 
 
Fig. (1). Assessment of endothelial cell lines EPCR mRNA synthesis (A) and protein expression (B). 
(A) EPCR amplification was performed on HBMEC cDNA, using specific primers. An expected band at 692bp was observed. A negative 
control, realized without cDNA, was run concurrently (panel A, second lane). DNA ladder is displayed in the first lane.  
(B) EPCR proteins were detected on endothelial cells by immunocytochemistry. Cells were grown in glass bottom chamber slides, rapidly 
fixed and successively incubated with EPCR specific antibodies (20 g/ml) and appropriate FITC-coupled secondary antibodies. Isotypic 
control was performed and nuclei were DAPI-labelled (first picture of panel B). Bound FITC was directly observed on a fluorescence micro-
scope (initially x60, scale bars represent 10 m). Big white arrows show nuclei, little arrows show cell extension. 
Table 1.  Optical Density of aPTT mix, Before and After Coagulation, Obtained at Different Wavelengths 
Wavelenght (nm)  O.D. Unclotted  O.D. Clotted  Ratio 
355 0,446  1,385 3,11 
405 0,493  1,365 2,77 
490 0,267  0,989 3,70 
540 0,115  0,767 6,67 
595 0,076  0,642 8,45 
Plasma and PTT-LA (100 L each) were incubated 3min at 37°C in a 96-well plate. CaCl2 (100L) was added to the mix to trigger coagulation. Clot formation was followed by 
spectrophotometer at various wavelengths. A measure was realized every minute. This table represents absorbance of the mix before and after fibrinoformation. The ratios (O.D. 
clotted/O.D. unclotted) of these absorbancies are displayed in the last column.  52    The Open Biochemistry Journal, 2009, Volume 3  Ducros et al. 
at 4°C to avoid EPCR internalization. APTT was then per-
formed onto cells carefully washed after exposure to differ-
ent levels of APC. The coagulation time shift induced by 
APC is highly appreciable and exhibits a dose-dependent 
response (Fig. 3A). Data in Fig. (3B) also indicate that 5 min 
incubation with 10 g/mL APC is sufficient to increase 
aPTT. Nevertheless, a longer incubation was chosen to opti-
mize the experiments. 
  Finally, a dose-dependent aPTT was achieved with 
epithelial cells that do not express EPCR as demonstrated by 
FACS analysis (Fig. 4A). The aPTT was realised with the 
procedure previously described. As expected, no shift in the 
coagulation time was observed after APC incubation (Fig. 
4B). This result ensures that the cells were carefully washed 
after APC exposure and that the fibrinoformation delay was 
indeed due to EPCR ability to retain APC on the cell mem-
brane. 
  APTT remains a standard hemostatic screening test daily 
used throughout the world in clinical and research laborato-
ries. This easy and reproducible assay can furthermore 
evolve with study needs. APTT provides indeed an interest-
ing tool for long-term anticoagulant therapy control [25], for 
detection of fetal lung maturity with the use of amniotic fluid 
[26] or even for gene transfer monitoring in hemostasis dis-
orders [27]. 
  While number of soluble EPCR quantitative determina-
tion immunoassays already exist [28, 29], this aPTT-based 
method was designed to assess EPCR presence and function-
ality on cellular membrane. Contrary to classical aPTT, this 
new assay can take in account whole cells.  
  The present assay is suitable to estimate cellular EPCR 
expression and functionality since a significant and dose-
dependent fibrinoformation time shift is observed after APC 
incubation of endothelial cells. No delay is observed with 
EPCR-negative cells, which ensures that fibrinoformation 
time extension is imputed to APC attached to the cell mem-
brane via EPCR. This method was initially developed to as-
sess EPCR expression and functionality but could be easily 
extended to study the expression by any cell type (under-
neath or included into a clot) of any coagulation factors’ re-
ceptors. This aPTT-based assay could also assess global co-
agulant activity of cells. This could be efficient to study 
thromboembolic disorders as hypercoagulability that is fre-
quently associated with cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Fibrinoformation kinetics of a plasma with various 
concentration of APC. 
Plasma, PTT-LA (100 L each) and 20 L APC (from 0.1 to 100 
g/mL) or serum-free medium (control w/o APC) were incubated 
3min at 37°C. CaCl2 (100 L) was added to trigger the coagula-
tion. Fibrinoformation was followed by spectrophotometer.   
Absorbance was measured every minute.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Plasma fibrinoformation kinetics on endothelial cells, preincubated or not with APC. 
30,000 endothelial cells were seeded per well in a 96-well plate. When confluency reached 80%, cells were incubated at 4°C either 15 min 
with increasing dose of APC (A) or with 10 g/mL APC or serum-free medium (control w/o APC) for 5 or 15 min (B). Cells were thereafter 
carefully washed and incubated (3min, 37°C) with plasma and PTT-LA (100 L each). CaCl2 (100 L) was finally added to trigger the co-
agulation. Fibrinoformation was followed by spectrophotometer. Absorbance was measured every minute.  Endothelial Protein C Receptor Functionality Analysis  The Open Biochemistry Journal, 2009, Volume 3    53 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Plasma fibrinoformation kinetics on EPCR-negative 
cells, preincubated or not with APC. 
Epithelial cells were detached using Accutase and immunolabelled 
as previously described with EPCR antibodies or isotypic control. 
EPCR expression was analysed with FACS Calibur. The FACS 
cytogram is displayed in the bottom right of the panel. 
30  000 epithelial cells were seeded per well in a 96-well plate. 
When confluency reached 80%, cells were incubated with APC (1 
or 10 g/mL) or serum-free medium (control w/o APC) for 15 min, 
at 4°C. Cells were thereafter carefully washed and incubated (3min, 
37°C) with plasma and PTT-LA (100 L each). CaCl2 (100 L) 
was finally added to trigger the coagulation. Fibrinoformation was 
followed by spectrophotometer. Absorbance was measured every 
minute.  
 
ABBREVIATIONS 
PTT =  partial  thromboplastin  time 
aPTT  =  activated partial thromboplastin time 
APC =  activated  protein  C 
EPCR  =  endothelial protein C receptor 
HBMEC  =  human bone marrow endothelial cell 
FBS  =  fetal bovine serum 
FVa  =  activated factor V  
FVIIIa  =  activated factor V  
MMLV  =  Moloney Murine Leukemia Virus 
dNTP  =  3'désoxyribo nucleotide 5'-triphosphate 
FACS  =  Fluorescence Activated Cell Sorting 
vWF  =  Von Willebrand factor 
VEGF  R-2  =  Vascular endothelial growth factor   
receptor 2 
OD =  optical  density 
bp =  base  pair 
nm =  nanometer 
RT-PCR  = reverse transcription polymerase chain   
reaction 
FITC =  Fluoresceine  isothiocyanate 
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